Methods for treatment or prevention of damage resulting from radiation, trauma or shock
Inventors
Baker, Shenda M. • Wiesmann, William P.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12594296-B2
Publication Date
2026-04-07
Expiration Date
Abstract
Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.
Core Innovation
The invention relates to methods of reducing the severity or delaying the onset of sepsis or reducing the likelihood of mortality in a subject. The method includes identifying a subject that will be exposed to radiation from a dirty bomb, accidental nuclear incident, or therapeutic treatment, and administering a therapeutically effective amount of a compound prior to exposure to radiation.
The compound used in the method is a compound of Formula (I), where n is an integer between 20 and 6000. Each R1 is independently selected for each occurrence from hydrogen and acetyl, and at least 25% of the R1 substituents are H, at least 1% of the R1 substituents are acetyl, and at least 2% of the R1 substituents are further substituted groups.
The described approach is configured to reduce sepsis severity, delay sepsis onset, or reduce the likelihood of mortality associated with radiation exposure. The document further emphasizes GI injury and leaky gut, including reduction of bacterial translocation and inflammation, and protection of mucosal lining including epithelial, crypt, and villous protection; it also addresses mucositis.
Claims Coverage
The partial content includes one independent claim with dependent claims that refine the radiation scenario and quantitative characteristics of the compound. The central coverage is the prophylactic administration of a Formula (I) compound prior to radiation exposure to achieve reductions in sepsis severity, delays in onset, or reduced likelihood of mortality.
Identifying a radiation-exposed subject and administering a Formula (I) compound prior to exposure
Identifying a subject that will be exposed to radiation from a dirty bomb, accidental nuclear incident, or therapeutic treatment; and administering, prior to exposure, a therapeutically effective amount of a compound of Formula (I) to reduce the severity or delay the onset of sepsis or to reduce the likelihood of mortality.
R1 composition constraints for the Formula (I) compound
A Formula (I) compound with n between 20 and 6000, where each R1 is independently selected for each occurrence from hydrogen and acetyl, and where at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and at least 2% of R1 substituents are substituted groups.
Radiation source refinement to dirty bomb or accidental nuclear incident
The method is carried out when the radiation originates from a dirty bomb or an accidental nuclear incident.
Targeting radiation-related sepsis risk
The method is used for a subject at risk of developing sepsis due to radiation exposure.
Molecular weight range limitation for the compound
The method is carried out using a compound whose molecular weight is within 50 to 150 kDa.
Polydispersity index range limitation for the compound
The method is defined such that the polydispersity index of the compound is within the range 1.0 to 2.5.
Radiation severity defined by a lethality threshold
The method is performed using radiation in an amount sufficient to produce 30% to 80% lethality.
Across the independent claim and its dependents, the claim coverage centers on prophylactic administration of a therapeutically effective Formula (I) compound prior to radiation exposure, with explicit R1 composition constraints, optionally further limited by radiation scenario, compound molecular weight, polydispersity index, and a radiation lethality threshold.
Stated Advantages
Reducing the severity of sepsis.
Delaying the onset of sepsis.
Reducing the likelihood of mortality.
Reducing the severity or delaying the onset of sepsis in a subject exposed to radiation.
Reducing the likelihood of mortality in a subject exposed to radiation.
Documented Applications
Reducing the severity of sepsis, delaying its onset, or reducing mortality likelihood in subjects exposed to radiation from a dirty bomb.
Reducing the severity of sepsis, delaying its onset, or reducing mortality likelihood in subjects exposed to radiation from an accidental nuclear incident.
Reducing the severity of sepsis, delaying its onset, or reducing mortality likelihood in subjects exposed to radiation from a therapeutic treatment.
Interested in licensing this patent?